Mandy Carter
Acute Care · Texarkana, TXNPI 1699066969
Payments from drug & device makers
Across 400 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Sanofi$749
- Boehringer Ingelheim$621
- Mylan Specialty L.p.$555
- AstraZeneca$396
- Mallinckrodt Hospital Products Inc.$364
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,349100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 111 | $1,703 |
| Sanofi | 30 | $749 |
| Boehringer Ingelheim | 28 | $621 |
| Mylan Specialty L.p. | 30 | $555 |
| AstraZeneca | 22 | $396 |
| Mallinckrodt Hospital Products Inc. | 16 | $364 |
| Insmed, Inc. | 24 | $349 |
| AbbVie | 21 | $325 |
| Regeneron Healthcare Solutions, Inc. | 17 | $323 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $279 |
| Electromed, Inc. | 13 | $207 |
| Grifols USA, LLC | 9 | $188 |
| Philips North America LLC | 10 | $166 |
| Actelion Pharmaceuticals US, Inc. | 5 | $158 |
| United Therapeutics Corporation | 3 | $124 |
| Pfizer | 7 | $108 |
| Novo Nordisk | 5 | $103 |
| Alnylam Pharmaceuticals Inc. | 4 | $83 |
| Eisai Inc. | 5 | $77 |
| Inspire Medical Systems, Inc. | 1 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Gilead | 3 | $48 |
| Merck | 3 | $43 |
| Lilly USA, LLC | 2 | $40 |
| Viatris Specialty LLC | 1 | $34 |
| Verona Pharma, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Inogen, Inc. | 2 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$7,354 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 174 | $207,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $62,851 |
| Dupixent PenDupilumab | 14 | $52,225 |
| EliquisApixaban | 38 | $42,814 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $38,656 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $27,715 |
| OzempicSemaglutide | 21 | $23,359 |
| LinzessLinaclotide | 19 | $20,022 |
| TrintellixVortioxetine Hydrobromide | 13 | $16,486 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $14,503 |
| TrulicityDulaglutide | 13 | $12,552 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $11,091 |
| Dexlansoprazole DrDexlansoprazole | 19 | $7,913 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,576 |
| Sucralfate | 16 | $4,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $40 | $220,422187 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,703 | $90,565104 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $396 | $46,93157 claims |
| PfizerEliquis | $108 | $42,81438 claims |
| Novo NordiskOzempic | $103 | $23,35921 claims |
| AbbVieLinzess, Synthroid | $325 | $21,89240 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $279 | $16,48613 claims |
| Boehringer IngelheimCombivent Respimat | $621 | $14,50312 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $66 | $2,38519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Texarkana
- Carmen CoeTexarkana$9K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
- Leslie GutierrezHouston$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.